Pfizer disclosed clinical data and a broad development strategy for the ultra‑long‑acting GLP‑1 agent it acquired from Metsera. The company reported Phase 2 results showing meaningful placebo‑adjusted weight loss and said it will move the program into a large Phase 3 program comprising roughly 10 pivotal trials, including higher dosing arms. Pfizer positioned the drug as a once‑monthly maintenance option intended to compete with weekly and daily regimens. Executives said the Phase 2 data increase confidence in the Phase 3 plan but also signaled intent to test substantially higher doses than those used in Phase 2. The programmatic scale and dosing escalation indicate Pfizer is seeking both efficacy gains and differentiated convenience to capture share in an increasingly crowded obesity market. Investors reacted to the update with mixed sentiment: management framed the results as supportive, while analysts noted cross‑trial comparisons to incumbents and rivals are imperfect. The development underscores how large pharma is allocating big capital to next‑generation metabolic assets acquired in high‑value deals.